Find all the latest information in lymphoma and CLL, arranged by subtype and malignancy.
Outpatient administration of liso-cel: Preliminary results from the OUTREACH study
Due to concerns regarding adverse events (AEs), chimeric antigen receptor (CAR) T-cell therapies are predominantly...
Real-world outcomes in Germany with standard-of-care axi-cel and tisa-cel for large B-cell lymphoma
Following promising results in clinical trials, the CD19-targeted chimeric antigen receptor (CAR)...
Duvelisib receives a positive opinion from the EMA CHMP for the treatment of R/R CLL and refractory FL
On March 25, 2021, it was announced that duvelisib received a positive opinion from the European...
Japanese approval of lisocabtagene maraleucel for the treatment of R/R LBCL
On March 25, 2021, it was announced that the Japanese Ministry of Health, Labour, and Welfare approved the use of...
FDA biologics license application of ublituximab plus umbralisib for the treatment of CLL
On March 29, 2021, it was announced that a biologics license application (BLA) was submitted to the U.S. Food...
A four-factor prognostic model predicts outcome in patients with CLL treated with ibrutinib
Ibrutinib is a Bruton’s tyrosine kinase inhibitor with clinical efficacy for patients with...
EC approval of pembrolizumab for adult and pediatric patients with R/R cHL
On March 18, 2021, it was announced that the European Commission (EC) approved pembrolizumab, an anti-PD-1 monoclonal...
Can CD30 CAR T-cell consolidation improve outcomes after ASCT for patients with CD30+ lymphomas?
During the 2021 TCT Meetings Digital Experience, the Lymphoma Hub spoke to Marcie Riches, UNC-Chapel...
Aggressive B-cell lymphomas
ALK-positive large B-cell lymphoma
Diffuse large B-cell lymphoma
Epstein-Barr virus-positive diffuse large B-cell lymphoma
Germinal center B-cell-like
Gray zone lymphoma
High-grade B-cell lymphoma
High-grade B-cell lymphoma – double hit lymphoma
Intravascular large B-cell lymphoma
Primary cutaneous DLBCL, leg type
Primary DLBCL of the central nervous system
Primary mediastinal large B-cell lymphoma
Transformed follicular lymphoma
Classical Hodgkin lymphoma
Hodgkin lymphoma, not otherwise specified
Mixed cellularity classical Hodgkin lymphoma
Nodular lymphocyte-predominant Hodgkin lymphoma
Nodular sclerosis classical Hodgkin lymphoma
Indolent B-cell lymphomas
Hairy cell leukemia
Hairy cell leukemia variant
In situ follicular neoplasia
Marginal zone lymphoma
Nodal marginal zone lymphoma
Pediatric-type follicular lymphoma, pediatric-type nodal follicular lymphoma
Primary cutaneous marginal zone lymphoma
Splenic marginal zone lymphoma
Mantle cell lymphomas
In situ mantle cell neoplasia
Mantle cell lymphoma
Mature T and NK cell neoplasms
Adult T-cell leukemia/lymphoma
Aggressive NK-cell leukemia
Anaplastic large cell lymphoma, ALK-negative
Anaplastic large cell lymphoma, ALK-positive
Angioimmunoblastic T-cell lymphoma
Breast implant-associated anaplastic large cell lymphoma
Cutaneous T-cell lymphoma
Enteropathy-associated T-cell lymphoma
Epstein-Barr virus-positive T-cell lymphoma
Extranodal NK/T-cell lymphoma, nasal type
Follicular T-cell lymphoma
Hepatosplenic T-cell lymphoma
Monomorphic epitheliotropic intestinal T-cell lymphoma
Nodal peripheral T-cell lymphoma with TFH phenotype
Peripheral T-cell lymphoma
Primary cutaneous acral CD8+ T-cell lymphoma
Primary cutaneous anaplastic large cell lymphoma
Primary cutaneous CD30+ T-cell lymphoproliferative disorders
Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder
Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma
Subcutaneous panniculitis-like T-cell lymphoma
T-cell prolymphocytic leukemia
Monoclonal B-cell lymphocytosis
Chronic lymphocytic leukemia
Small lymphocytic lymphoma
Classical Hodgkin lymphoma post-transplant lymphoproliferative disorders
Post-transplant lymphoproliferative disorders